Tampere spin-off building scalable iPSC-derived corneal cell therapy for limbal stem cell deficiency, targeting first clinical trials around 2027.
Finnish corneal cell therapy — ophthalmology overlap.
Evidence from the records
- “Pleryon Therapeutics”
- “Ophthalmic cell therapy (cornea)”
- “Corneal cell therapy at preclinical stage, clinical trials targeted around 2027”
- Intro path
- Founder-to-founder intro via Pleryon Therapeutics (network portfolio company of Lapam Capital).
- First step
- Qualify via Pleryon.